GHB used to be available as a dietary supplement in the U.S., but it was taken off the market in 1990 because of safety concerns. It is now a Schedule I controlled substance, making it illegal to produce, sell, or possess. A prescription form of GHB called sodium oxybate (Xyrem) is still available for treating excessive daytime sleepiness (narcolepsy). It is a Schedule III controlled substance, which means that it requires a prescription and close monitoring by a medical doctor.
The prescription form of GHB is used for excessive daytime sleepiness (narcolepsy). It has also been used for alcohol use disorder and opioid withdrawal.
How does it work ?
Uses & Effectiveness ?
- Excessive daytime sleepiness (narcolepsy). Taking GHB helps people with narcolepsy sleep at night so they are less likely to feel sleepy during the day. GHB also reduces other symptoms that sometimes go along with narcolepsy.
Possibly Effective for
Insufficient Evidence for
GHB adds to the effects of alcohol and many drugs that cause sleepiness.
When given by IV: GHB is POSSIBLY SAFE when given by IV under close medical supervision, short-term.
Special Precautions and Warnings
Slow heart rate (bradycardia): GHB should be avoided since it can slow the heart rate.
Seizure disorder (Epilepsy): GHB might cause seizures in people with epilepsy. Avoid use.
Surgery: GHB can affect the central nervous system. There is a concern that it might cause too much sleepiness if it is used along with anesthesia and other nerve-numbing medications used during and after surgery. Stop using GHB at least 2 weeks before a scheduled surgery. Talk to your doctor before stopping sodium oxybate (Xyrem).
Alcohol (Ethanol) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Concomitant use may increase the risk of serious CNS and respiratory depression (3678,102834). Ethanol may also inhibit the clearance of GHB (3682,102831). Research also shows that concomitant use can increase the risk of other adverse events, including gastrointestinal disturbances , hypotension, and decreased oxygen saturation (93831).
Amphetamines interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Amphetamines are drugs that can speed up your nervous system. GHB can slow down your nervous system. Taking GHB along with amphetamines can lead to serious side effects.
Haloperidol (Haldol) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
GHB can affect the brain. Haloperidol (Haldol) can also affect the brain. Taking haloperidol (Haldol) along with GHB might cause serious side effects.
Medications for mental conditions (Antipsychotic drugs) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
GHB can affect the brain. Medications for mental conditions also affect the brain. Taking GHB along with medications for mental conditions might increase the effects and serious side effects of GHB. Do not take GHB if you are taking medications for a mental condition.
Some of these medications include fluphenazine (Permitil, Prolixin), haloperidol (Haldol), chlorpromazine (Thorazine), prochlorperazine (Compazine), thioridazine (Mellaril), trifluoperazine (Stelazine), and others.
Medications used to prevent seizures (Anticonvulsants) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Medications used to prevent seizures affect chemicals in the brain. GHB is changed in the body to one of these brain chemicals called GABA. Taking GHB along with medications used to prevent seizures might decrease the effects of GHB.
Some medications used to prevent seizures include phenobarbital, primidone (Mysoline), valproic acid (Depakene), gabapentin (Neurontin), carbamazepine (Tegretol), phenytoin (Dilantin), and others.
Muscle relaxants interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Muscle relaxants can cause drowsiness. GHB can also cause drowsiness. Taking GHB along with muscle relaxants might cause too much drowsiness and serious side effects. Do not take GHB if you are taking muscle relaxants.
Some of these muscle relaxants include carisoprodol (Soma), pipecuronium (Arduan), orphenadrine (Banflex, Disipal), cyclobenzaprine, gallamine (Flaxedil), atracurium (Tracrium), pancuronium (Pavulon), succinylcholine (Anectine), and others.
Naloxone (Narcan) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
GHB can affect the brain. Taking naloxone (Narcan) along with GHB might decrease the effects of GHB on the brain.
Ritonavir (Norvir) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Ritonavir (Norvir) and saquinavir (Fortovase, Invirase) are commonly used together for HIV/AIDS. Taking both of these medications plus GHB might decrease how quickly the body gets rid of GHB. This could cause serious side effects.
Saquinavir (Fortovase, Invirase) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Saquinavir (Fortovase, Invirase) and ritonavir (Norvir) are commonly used together for HIV/AIDS. Taking both these medications plus GHB might decrease how fast the body gets rid of GHB. This could cause serious side effects.
Sedative medications (CNS depressants) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
GHB might cause sleepiness and drowsiness. Medications that cause sleepiness are called sedatives. Taking GHB along with sedative medications might cause serious side effects. Do not take GHB if you are taking sedative medications.
Some sedative medications include clonazepam (Klonopin), lorazepam (Ativan), phenobarbital (Donnatal), zolpidem (Ambien), and others.
Sedative medications (Benzodiazepines) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
GHB (BD) might cause sleepiness and drowsiness. Medications that cause sleepiness and drowsiness are called sedatives. Taking GHB along with sedative medications might cause serious side effects. Do not take GHB if you are taking sedative medications.
Some of these sedative medications include clonazepam (Klonopin), diazepam (Valium), lorazepam (Ativan), and others.
Do not take this combination
Medications for pain (Narcotic drugs) interacts with GAMMA-HYDROXYBUTYRATE (GHB)
Some medications for pain can cause sleepiness and drowsiness. GHB might also cause sleepiness and drowsiness. Taking GHB along with some medications for pain might cause severe side effects. Do not take GHB if you are taking medications for pain.
Some medications for pain include meperidine (Demerol), hydrocodone, morphine, OxyContin, and many others.
Be cautious with this combination
- For excessive daytime sleepiness (narcolepsy): A dose of 25 mg/kg at bedtime, repeated 3 hours later, or a total of with sedative properties.
- For alcohol use disorder:50 to 150 mg/kg divided into 3 to 6 doses per day. GHB should be used only under close medical supervision.
- For alcohol use disorder: 50-100 mg/kg divided into 4 doses per day has been used. GHB should be used only under close medical supervision.
Abanades S, Farré M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006 Aug;1074:559-76. View abstract.
Addolorato G, Cibin M, Caprista E, et al. Maintaining abstinence from alcohol with gamma hydroxybutyric acid. [Letter] Lancet 1998;351:38.
Anon. FDA alert on misuse of consumer products containing GHB, GBL and BD. Food and Drug Administration, Rockville, MD. June 15, 1999. Available at: https://www.fda.gov/cder/graphics/ghb.gif
Anon. Important message for health professionals: Report serious adverse events associated with dietary supplements containing GBL, GHB or BD. Food and Drug Administration, Rockville, MD. August 25, 1999. Available at: https://vm.cfsan.fda.gov/~dms/mwgblghb.html
Anon. Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. JAMA 1991;265:447-8.
Bosch OG, Eisenegger C, Gertsch J, et al. Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology. 2015 Dec;62:1-10. View abstract.
Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012 Oct;16(5):431-43. View abstract.
Brennan R, Van Hout MC. Gamma-hydroxybutyrate (GHB): a scoping review of pharmacology, toxicology, motives for use, and user groups. J Psychoactive Drugs. 2014 Jul-Aug;46(3):243-51. View abstract.
Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci 1979;6:1-6. View abstract.
Carotenuto A, De Feo V, Fattorusso E, et al. The flavonoids of Allium ursinum. Phytochem 1996;41:531-6. View abstract.
Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent (abstract). Neurosci Biobehav Rev 1994;18:291-304. View abstract.
Cash CD. What is the role of the gamma-hydroxybutyrate receptor? Med Hypotheses 1996;47:455-9. View abstract.
Dornbierer DA, Kometer M, Von Rotz R, et al. Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. Eur Neuropsychopharmacol 2019;29(4):539-48. doi: 10.1016/j.euroneuro.2019.02.004. View abstract.
Drogies T, Willenberg A, Ramshorn-Zimmer A, et al.. Detection of gamma hydroxybutyrate in emergency department: Nice to have or a valuable diagnostic tool? Hum Exp Toxicol. 2016 Jul;35(7):785-92. View abstract.
Dyer J, Roth B, Hyma B. Gamma-Hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37:147-53.. View abstract.
Dyer JE. Gamma-Hydroxybutyrate: a health-food product producing coma and seizure-like activity (abstract). Am J Emerg Med 1991;9:321-4. View abstract.
FDA Talk Paper. FDA Warns About GBL-Related Products. 1999. Available at: vm.cfsan.fda.gov/~lrd/tpgbl2.html
FDA Talk Paper. FDA Approves Xyrem for Cataplexy Attacks in Patients with Narcolepsy. Issued July 17, 2002. Availbale at: https://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01157.html
Feigenbaum JJ, Howard SG. Gamma hydroxybutyrate is not a GABA agonist (abstract). Prog Neurobiol 1996;50:1-7. View abstract.
Ferrara SD, Tedeschi L, Frison G, Rossi A. Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. J Forensic Sci 1995;40:501-4. View abstract.
Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989;2:787-9. View abstract.
Gallimberti L, Cibin M, Pagnin P, et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology 1993;9:77-81. View abstract.
Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-Hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992;16:673-6. View abstract.
Gallimberti L, Schifano F, Forza G, et al. Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. Eur Arch Psychiatry Clin Neurosci 1994;244:113-4. View abstract.
Galloway GP, Frederick SL, Staggers FE Jr, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997;92:89-96. View abstract.
Gerra G, Caccavari R, Fontanesi B, et al. Naloxone and metergoline effects on growth hormone response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1995;10:245-50. View abstract.
Harrington RD, Woodward JA, Hooton TM, et al. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159:2221-4. View abstract.
Hillory J. Farias and Samantha Reid date-rape drug prohibition act of 2000. 106th Congress of the United States of America. HR 2130.
Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980;6:93-9. View abstract.
Ingels M, Rangan C, Bellezzo J, Clark R. Coma and respiratory depression following the ingestion of GHB and its precursors: Three cases. J Emerg Med 2000;19:47-50.. View abstract.
Kalra MA, Hart LL. Gammahydroxybutyrate in narcolepsy. Ann Pharmacother 1992;26:647-8.
Kuiper MA, Peikert N, Boerma EC. Gamma-hydroxybutyrate withdrawal syndrome: a case report. Cases J. 2009 Mar 25;2:6530. View abstract.
Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006266. View abstract.
Liakoni E, Dempsey DA, Meyers M, et al. Effect of ?-hydroxybutyrate (GHB) on driving as measured by a driving simulator. Psychopharmacology (Berl) 2018;235(11):3223-32. doi: 10.1007/s00213-018-5025-2. View abstract.
Maitre M. The gamma-hydroxybutyrate signaling system in brain: organization and functional implications (abstract). Prog Neurobiol 1997;51:337-61. View abstract.
Mamelak M. Gammahydroxybutyrate: an endogenous regulator of energy metabolism (abstract). Neurosci Biobehav Rev 1989;13:187-98. View abstract.
Mason P, Kerns II W. Gamma Hydroxybutyric Acid (GHB) Intoxication. Acad Emerg Med 2002;9:730-39.. View abstract.
Nava F, Premi S, Manzato E, Campagnola W, Lucchini A, Gessa GL. Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open study vs. diazepam. Am J Drug Alcohol Abuse. 2007;33(3):379-92. View abstract.
Németh Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol. 2010 Sep;24(9):1281-7. View abstract.
Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM. Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002 Jan-Feb;37(1):67-73. View abstract.
Oliveto A, Gentry WB, Pruzinsky R, et al. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol. 2010 Jul;21(4):332-42. View abstract.
Otto A. Acquaintance rape drug may one day help instead of hurt (news). Pharmacy Today. American Pharmaceutical Association, Washington, DC. April 2000:17.
Price G. In-patient detoxification after GHB dependence. Br J Psychiatry 2000;177:181.
Raposo Pereira F, McMaster MTB, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Adverse effects of GHB-induced coma on long-term memory and related brain function. Drug Alcohol Depend 2018;190:29-36. doi: 10.1016/j.drugalcdep.2018.05.019. View abstract.
Rousseau AF, Ledoux D, Sabourdin N, Richard P, Damas P, Constant I. Clinical sedation and bispectral index in burn children receiving gamma-hydroxybutyrate. Paediatr Anaesth. 2012 Aug;22(8):799-804. View abstract.
Scharf MB, Brown D, Woods M, et al. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry 1985;46:222-5. View abstract.
Scharf MB, Hauck M, Stover R, et al. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Preliminary report. J Rheumatol 1998;25:1986-90. View abstract.
Scrima L, Hartman PG, Johnson FH Jr, et al. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990;13:479-90. View abstract.
Scrima L, Hartman PG, Johnson FH Jr, Hiller FC. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol Psychiatry 1989;26:331-43. View abstract.
Smith KM. Drugs used in acquaintance rape. J Am Pharm Assoc 1999;39:519-25. View abstract.
Stomberg MW, Knudsen K, Stomberg H, Skärsäter I. Symptoms and signs in interpreting gamma-hydroxybutyrate (GHB) intoxication - an explorative study. Scand J Trauma Resusc Emerg Med. 2014 Apr 23;22:27. View abstract.
Thai D, Dyer JE, Benowitz NL, Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Psychopharmacol. 2006 Oct;26(5):524-9. View abstract.
Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):178-84. View abstract.
Timby N, Eriksson A. Gamma-Hydroxybutyrate-Associated Deaths. Am J Med 2000;108:518.
Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol 1992;23:1027-34. View abstract.
Tunnicliff, G. Sites of action of gamma-hydroxybutyrate (GHB)-a neuroactive drug with abuse potential. J Toxicol Clin Toxicol 1997;35:581-90. View abstract.
Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young Men (abstract). J Clin Invest 1997;100:745-53. View abstract.
van Noorden MS, Kamal RM, Dijkstra BA, Mauritz R, de Jong CA. A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics. 2015 Jul-Aug;56(4):404-9. View abstract.
Weiss T, Müller D, Marti I, Happold C, Russmann S. Gamma-hydroxybutyrate (GHB) and topiramate--clinically relevant drug interaction suggested by a case of coma and increased plasma GHB concentration. Eur J Clin Pharmacol. 2013 May;69(5):1193-4.View abstract.
Xu XM, Wei YD, Liu Y, Li ZX. Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis. Sleep Med 2019;64:62-70. doi: 10.1016/j.sleep.2019.06.017. View abstract.
Xyrem - sodium oxybate solution Prescribing Information. Jazz Pharmaceuticals, Inc., Palo Alto, CA. October 2018.
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.